Ellsworth Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,167 shares of the company’s stock after purchasing an additional 2,058 shares during the period. Johnson & Johnson makes up approximately 1.6% of Ellsworth Advisors LLC’s holdings, making the stock its 10th largest holding. Ellsworth Advisors LLC’s holdings in Johnson & Johnson were worth $6,243,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the stock. Summit Wealth Partners LLC boosted its holdings in Johnson & Johnson by 0.6% in the second quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock valued at $1,463,000 after acquiring an additional 61 shares in the last quarter. Powers Advisory Group LLC boosted its stake in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after purchasing an additional 61 shares in the last quarter. Eagle Wealth Strategies LLC increased its position in shares of Johnson & Johnson by 2.8% during the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after buying an additional 63 shares during the period. Knuff & Co LLC lifted its holdings in Johnson & Johnson by 0.7% in the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after buying an additional 64 shares during the period. Finally, Perkins Coie Trust Co boosted its position in Johnson & Johnson by 1.8% during the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock valued at $600,000 after acquiring an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the company. Royal Bank of Canada raised their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Barclays lowered their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a report on Tuesday. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $173.27.
Insider Buying and Selling
In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $148.10 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock’s fifty day moving average price is $148.35 and its 200-day moving average price is $156.11. The firm has a market cap of $356.57 billion, a P/E ratio of 21.43, a P/E/G ratio of 2.39 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.35%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
- Five stocks we like better than Johnson & Johnson
- Ride Out The Recession With These Dividend Kings
- SAP’s Strong Momentum: A Bullish Setup for Investors
- How Can Investors Benefit From After-Hours Trading
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Dividend Capture Strategy: What You Need to Know
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.